Wall Street analyst estimates for Minerva Neurosciences, Inc. (NERV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Valuation Ratios
| Price / Book | -0.78 |
| EV / EBITDA | -0.46 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $41.2M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $11094 | $17467 | $161507 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$16530 | -$11094 | -$17467 | -$162000 | $41.2M | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $20.4M | $30.3M | $34.9M | $58.1M | $22.0M | $32.0M | $14.6M | $12.7M | $11.9M | $5.8M |
| Selling, General & Admin | $9.8M | $10.9M | $16.8M | $17.7M | $17.3M | $13.3M | $10.6M | $10.4M | $9.9M | $9.3M |
| Operating Expenses | $30.2M | $41.2M | $51.7M | $75.9M | $39.3M | $45.4M | $25.2M | $23.1M | $21.8M | $15.1M |
| Operating Income | -$30.2M | -$41.2M | -$51.7M | -$75.9M | $1.8M | -$45.4M | -$25.2M | -$23.1M | -$21.8M | -$15.1M |
| EBITDA | -$30.0M | -$40.3M | -$50.0M | -$74.3M | $2.1M | -$45.3M | -$24.7M | -$21.7M | $6.0M | -$293.4M |
| Interest Expense | $1.0M | $614264 | $110448 | 0 | 0 | $6.3M | $7.4M | $8.3M | $4.6M | 0 |
| Pre-tax Income | -$31.0M | -$40.9M | -$50.2M | -$74.4M | $1.9M | -$51.7M | -$32.1M | -$30.0M | $1.4M | -$293.4M |
| Income Tax | 0 | -$9.4M | $1.7M | -$2.3M | 0 | -$1.8M | 0 | 0 | 0 | 0 |
| Net Income | -$31.0M | -$31.5M | -$50.2M | -$72.2M | $1.9M | -$49.9M | -$32.1M | -$30.0M | $1.4M | -$293.4M |
| EPS | $-7.88 | $-6.65 | $-10.35 | $-14.80 | $0.38 | $-9.35 | $-6.01 | $-4.61 | $0.19 | $-34.67 |
| EPS (Diluted) | $-7.88 | $-6.65 | $-10.35 | $-14.80 | $0.38 | $-9.35 | $-6.01 | $-4.61 | $0.19 | $-34.67 |
| Shares Outstanding (Diluted) | $3.9M | $4.7M | $4.8M | $4.9M | $5.1M | $5.3M | $5.3M | $6.5M | $7.6M | $8.5M |
Price
| Price | $3.48 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLGN · CVKD · ENLV · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NERV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks